温馨提示：本站仅提供公开网络链接索引服务，不存储、不篡改任何第三方内容，所有内容版权归原作者所有
AI智能索引来源：http://www.msd.com/investor-relations
点击访问原文链接

Investor relations - MSD

进入原网站 导航首页
Investor relations - MSD Skip to content

Search everything Close Menu Close Main menu Company Who we are What we do Stories History Sustainability Sustainability overview Philanthropy MSD Medical Outreach Program Impact Venture Fund Transparency disclosures Sustainability resources Leadership Leadership overview Board of directors Executive team Culture & values Culture & values overview Code of conduct, ethics and compliance Diversity and inclusion Policies and positions Suppliers Suppliers overview Supplier registration Supplier help for Ariba Research Research overview Areas of focus Oncology Vaccines Infectious diseases Cardiovascular disease Immunology Neuroscience Ophthalmology Areas of innovation Data science and artificial intelligence Green and sustainable science Our therapeutic modalities Translational medicine Pipeline Business development and licensing Clinical Trials Clinical trials overview Diversity in clinical trials R&D locations How we invent Meet our scientists Publications Safety data sheets (SDS) Product patents Patients Patients overview Play an active role in your health care Fighting counterfeit medicine Media Media overview News releases Company statements Company fact sheet Investors Investors overview Events and presentations Stock information Careers Who we are Learn more Contact us What can we help you find? Search for: Investor relations Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
March 2, 2026 5:28 pm ET
Delayed at least 20 minutes

View stock information

Latest news, events, & financials NewsEvents and presentationsFinancials February 3, 2026

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

October 30, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

July 29, 2025

Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results

4 April 30, 2026

Earnings

Q1 2026 Earnings Call

Apple Calendar Google Calendar Outlook Calendar iCalendar August 04, 2026

Earnings

Q2 2026 Earnings Call

Apple Calendar Google Calendar Outlook Calendar iCalendar October 29, 2026

Earnings

Q3 2026 Earnings Call

Apple Calendar Google Calendar Outlook Calendar iCalendar View all

  4Q25 MSD Earnings Announcement

  4Q25 MSD Other Financial Disclosures

  4Q25 Other Financial Disclosures (Excel)

  4Q25 Prepared Remarks Q1 2026 Earnings Call April 30, 2026

Apple Calendar Google Calendar Outlook Calendar iCalendar

See full agenda Our pipeline shows our relentless pursuit of the next breakthrough. Explore our pipeline Phase II programs 50+

Phase III programs 30+

Under review 5+

Our leadership Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership × Sustainability Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Purpose for Progress Impact Report 2024/2025

× Download our Sustainability financing documents 2023 Sustainability bond allocation report

2022 Sustainability bond allocation report

We're led by our science We follow the science to our next breakthrough, leaving no stone unturned.

View our stories Innovation Our Q2 2025 financial results MSD’s Q2 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q2 worldwide sales of $15.8 billion.​ “Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example of acting […]

Read more Innovation Our Q1 2025 financial results MSD’s Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion.​ ​”Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman and chief […]

Read more Innovation Our Q4 and full-year 2024 financial results MSD’s Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. ​ ​“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, […]

Read more Innovation Our Q2 2025 financial results MSD’s Q2 2025 sales performance reflects strength across oncology and animal health, as well as increasing contributions from new launches. Our company announced Q2 worldwide sales of $15.8 billion.​ “Earlier this month, we were pleased to announce our pending acquisition of Verona Pharma, which augments our portfolio and pipeline and is another example of acting […]

Read more Next: Our Q2 2025 financial results

Innovation Our Q1 2025 financial results MSD’s Q1 2025 results reflect strong progress, including increasing contributions from newer medicines and vaccines. Our company announced Q1 worldwide sales of $15.5 billion.​ ​”Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline,” said Rob Davis, chairman and chief […]

Read more Next: Our Q1 2025 financial results

Innovation Our Q4 and full-year 2024 financial results MSD’s Q4 and full-year 2024 results reflect strong growth. Our company announced Q4 worldwide sales of $15.6 billion, an increase of 7% from Q4 2023. Full-year 2024 worldwide sales were $64.2 billion, an increase of 7% from full-year 2023. ​ ​“We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including for KEYTRUDA, […]

Read more Next: Our Q4 and full-year 2024 financial results

Previous Next For questions, please contact our team. Contact investor relations Phone icon +1 (732) 594-1468 Email icon Email our team Connect with us on social For patients and health care professionals MSD Manuals
Medical information source covering thousands of topics in all fields of medicine Clinical trials
Learn about our clinical trials and find available studies Sustainability Impact Report
Reporting on our commitment to operating responsibly to benefit society MSD for Mothers
An initiative to create a world where no woman has to die giving life About MSD MSD Animal Health
The global animal health business unit of MSD Contact Us
If you have a question or need more information about us, find out who you should contact. Forward-looking statementCookie policyCookie PreferencesPrivacyTerms of useAccessibilitySitemap Copyright © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept

智能索引记录